Abstract
Introduction
Alzheimer’s disease (AD) is the cause of more than two-thirds of all dementia cases. Although there is no effective treatment against this disorder, its association with neuroinflammation suggests that non-steroidal anti-inflammatory drugs (NSAIDs) might represent a potential therapeutic option.
Objective
The objective of this study was to evaluate the efficacy of NSAIDs in the treatment of AD using a meta-analysis approach.
Methods
MEDLINE, Web of Science, Science Direct, and the Cochrane Library were used to search all the randomized controlled trials that have evaluated the efficacy of NSAIDs as a treatment for AD (up to 1 October 2014). The overall effect of NSAIDs versus placebo was determined using a random effects model meta-analysis where we compared changes (i.e., mean differences pre- vs. post-treatment) between the two conditions in test scores indicative of cognition, disease severity, and related outcomes.
Results
Seven studies were finally included in the meta-analysis. Diclofenac/misoprostol, nimesulide, naproxen, rofecoxib, ibuprofen, indomethacin, tarenflurbil, and celecoxib were the NSAIDs used in these reports. The results of the AD Assessment Scale–cognitive subscale (ADAS–cog), the Clinical Dementia Rating Scale sum-of-boxes (CDR-SOB), and the Mini-Mental State Examination (MMSE) showed no statistical or clinical significance of NSAIDs treatment compared with placebo, i.e., mean differences of −0.24 (95 % Confidence Interval (CI) −1.04 to 0.57; P = 0.52), −0.07 (95 % CI −0.7 to 0.56; P = 0.82), and 0.35 (95 % CI −0.34 to 1.04; P = 0.32), respectively.
Conclusion
Current preliminary evidence suggests no beneficial effect of NSAIDs on cognition or overall AD severity. Thus, although more research is needed in the field, the evidence available does not support the use of NSAIDs for AD treatment.




Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology. 1996;47(2):425–32.
Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol. 1997;41(1):17–24.
Golde TE. Inflammation takes on Alzheimer disease. Nat Med. 2002;8(9):936–8.
Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, et al. Inflammatory components in human Alzheimer’s disease and after active amyloid-beta42 immunization. Brain. 2013;136(Pt 9):2677–96.
Eikelenboom P, van Gool WA. Neuroinflammatory perspectives on the two faces of Alzheimer’s disease. J Neural Transm. 2004;111(3):281–94.
Zhu X, Lee HG, Perry G, Smith MA. Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta. 2007;1772(4):494–502.
Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA, Mirage Study Group. Nonsteroidal anti-inflammatory drug use and Alzheimer’s disease risk: the MIRAGE study. BMC Geriatr. 2005;5:2.
Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review. Neuroepidemiology. 2004;23(4):159–69.
Thal LJ. Anti-inflammatory drugs and Alzheimer’s disease. Neurobiol Aging. 2000;21(3):449–50 (discussion 51–3).
Kolibas E, Korinkova V, Novotny V, Vajdickova K, Hunakova D. ADAS–cog (Alzheimer’s Disease Assessment Scale–cognitive subscale)—validation of the Slovak version. Bratisl Lek Listy. 2000;101(11):598–602.
Tschanz JT, Corcoran CD, Schwartz S, Treiber K, Green RC, Norton MC, et al. Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry. 2011;19(6):532–42.
Hamrick I, Hafiz R, Cummings DM. Use of days of the week in a modified mini-mental state exam (M-MMSE) for detecting geriatric cognitive impairment. J Am Board Fam Med. 2013;26(4):429–35.
Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol. 2006;6:50.
Babiloni C, Frisoni GB, Del Percio C, Zanetti O, Bonomini C, Cassetta E, et al. Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer’s disease. Clin Neurophysiol. 2009;120(4):709–18.
Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology. 1999;53(1):197–201.
Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer’s disease. Neurology. 2002;58(7):1050–4.
Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21):2819–26.
Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease. Aging Clin Exp Res. 2009;21(2):102–10.
de Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, Borm G, et al. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial. PloS One. 2008;3(1):e1475.
Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised phase II trial. Lancet Neurol. 2008;7(6):483–93.
Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302(23):2557–64.
Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2007;23(1):8–21.
Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66–71.
Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology. 1993;43(8):1609–11.
Sedwick P. Clinical significance versus statistical significance. BMJ. 2014;349(2130).
Yu F, Kolanowski AM, Strumpf NE, Eslinger PJ. Improving cognition and function through exercise intervention in Alzheimer’s disease. J Nurs Scholarsh. 2006;38(4):358–65.
Andersen CK, Wittrup-Jensen KU, Lolk A, Andersen K, Kragh-Sorensen P. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life outcomes. 2004;2:52.
Andrieu S, Reynish E, Nourhashemi F, Shakespeare A, Moulias S, Ousset PJ, et al. Predictive factors of acute hospitalization in 134 patients with Alzheimer’s disease: a one year prospective study. Int J Geriatr psychiatry. 2002;17(5):422–6.
Steeman E, Abraham IL, Godderis J. Risk profiles for institutionalization in a cohort of elderly people with dementia or depression. Arch Psychiatr Nurs. 1997;11(6):295–303.
Newcomer R, Covinsky KE, Clay T, Yaffe K. Predicting 12-month mortality for persons with dementia. J Gerontol B Psychol Sci Soc Sci. 2003;58(3):S187–98.
Glass GV, McGraw B, Smith ML. Meta-analysis in social sciences. Beverly Hills: Sage; 1984.
Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327(7407):128.
Breitner JC, Zandi PP. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer’s disease? N Engl J Med. 2001;345(21):1567–8.
Kalaria RN. Microglia and Alzheimer’s disease. Curr Opin Hematol. 1999;6(1):15–24.
Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J. 2009;23(8):2502–13.
Benzing WC, Wujek JR, Ward EK, Shaffer D, Ashe KH, Younkin SG, et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging. 1999;20(6):581–9.
Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer’s disease. Lancet Neurol. 2002;1(5):279–84.
Tuppo EE, Arias HR. The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol. 2005;37(2):289–305.
Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009;21(1):117–28.
Shohamy D, Turk-Browne NB. Mechanisms for widespread hippocampal involvement in cognition. J Exp Psychol Gen. 2013;142(4):1159–70.
Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology. 1997;48(3):626–32.
Hawkey CJ, Lanas AI, Sardinia NM. Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement. Am J Med. 2001;110(1A):79S–100S.
Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353(9149):307–14.
Conflict of interest
All the authors (Marina Miguel-Álvarez, Alejandro Santos-Lozano, Fabian Sanchis-Gomar, Helios Pareja-Galeano, Carmen Fiuza-Luces, Nuria Garatachea, and Alejandro Lucia) declare they have no conflict of interest.
Funding
The authors received no funding to conduct this meta-analysis.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Miguel-Álvarez, M., Santos-Lozano, A., Sanchis-Gomar, F. et al. Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect. Drugs Aging 32, 139–147 (2015). https://doi.org/10.1007/s40266-015-0239-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40266-015-0239-z